Idiopathic pulmonary fibrosis: Current trends in management

Clinics in Chest Medicine

Volumn 25, Issue 4 SPEC.ISS., 2004, Pages 621-636

  Raghu, Ganesh ^a   Chang, Jacqueline ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; COLCHICINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

BRONCHOSCOPY; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; FIBROSING ALVEOLITIS; GENETICS; HUMAN; IMAGING SYSTEM; LABORATORY DIAGNOSIS; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG SURGERY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY;

EID: 9444285533     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2004.08.002     Document Type: Review

References (57)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This official statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 Am J Respir Crit Care Med 165 2002 277
2. E.A. Gaensler, M.V. Ball-Moister, and J. Hamm Open lung biopsy in diffuse pulmonary disease N Engl J Med 270 1964 1319
3. P. Tukiainen, E. Taskinen, and P. Holsti Prognosis of cryptogenic fibrosing alveolitis Thorax 38 1983 349
4. C.P. Wall, E.A. Gaensler, and C.B. Carrington Comparison of transbronchial and open biopsies in chronic infiltrative lung disease Am Rev Respir Dis 23 1981 280
5. J.H. Ryu, T.V. Colby, and T.E. Hartman Idiopathic pulmonary fibrosis: current concepts Mayo Clin Proc 73 1993 1085
6. D.B. Coultas, R.E. Zumwalt, and W.C. Black The epidemiology of interstitial lung diseases Am J Respir Crit Care Med 150 1994 967
7. J. Scott, I. Johnston, and J. Britton What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust BMJ 301 1990 1015
8. R.P. Marshall, R.J. McAnulty, and G.J. Laurent The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Int J Biochem Cell Biol 29 1997 107
9. P.P. Bonanni, J.W. Frymoyer, and R.F. Jacox A family study of idiopathic pulmonary fibrosis. A possible dysproteinemic and genetically determined disease Am J Med 39 1965 411
10. A. Marney, K.B. Lane, and J.A. Phillips 3rd Idiopathic pulmonary fibrosis can be an autosomal dominant trait in some families Chest 120 2001 56S
11. J.E. Loyd Pulmonary fibrosis in families Am J Respir Cell Mol Biol 29 2003 S47
12. M.E. Hanley, T.E. King Jr, and M.I. Schwarz The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis Am Rev Respir Dis 144 1991 1102
13. D.A. Schwartz, R.K. Merchant, and R.A. Helmers The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis Am Rev Respir Dis 144 1991 504
14. K.B. Baumgartner, J.M. Samet, and D.B. Coultas Collaborating Centers. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study Am J Epidemiol 152 2000 307
15. J. Mullen, M.J. Hodgson, and C.A. DeGraff Case-control study of idiopathic pulmonary fibrosis and environmental exposures J Occup Environ Med 40 1998 363
16. R. Hubbard, S. Lewis, K. Richards, I. Johnston, and J. Britton Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis Lancet 347 1996 284 289
17. R. Hubbard, A. Venn, C. Smith, M. Cooper, I. Johnston, and J. Britton Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study Am J Respir Crit Care Med 157 3 Pt 1 1998 743 747
18. R.W. Tobin, C.E. Pope 2nd, C.A. Pellegrini, M.J. Emond, J. Sillery, and G. Raghu Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 158 1998 1804 1808
19. G. Raghu, L.J. Striker, L.D. Hudson, and G.E. Striker Extracellular matrix in normal and fibrotic human lungs Am Rev Respir Dis 131 1985 281 289
20. T.D. Freudenberger, J.R. Curtis, T. Eubanks, C.A. Pelligrini, and G. Raghu Prevalence and characteristic features of gastroesophageal reflux (GER) in patients with idiopathic pulmonary fibrosis (IPF) Am J Respir Crit Care Med 163 2001 A714
21. G. Raghu The role of gastroesophageal reflux in idiopathic pulmonary fibrosis Am J Med 15 Suppl 3 2003 60S 64S
22. A.A. Liebow, and C.B. Carrington The interstitial pneumonias 1st edition 1969 Grune and Stratton New York
23. American Thoracic Society (ATS) and the European Respiratory Society (ERS) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement Am J Respir Crit Care Med 161 2000 646 664
24. A.L. Katzenstein, and J.L. Myers Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification Am J Respir Crit Care Med 157 1998 1301
25. K.R. Flaherty, W.D. Travis, and T.V. Colby Histopathologic variability in usual and nonspecific interstitial pneumonias Am J Respir Crit Care Med 164 2001 1722
26. M. Selman, T.E. King, and A. Pardo American Thoracic Society; European Respiratory Society, and the American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy Ann Intern Med 134 2001 136 151
27. T.J. Gross, and G.W. Hunninghake Idiopathic pulmonary fibrosis N Engl J Med 345 2001 517 525
28. P.W. Noble Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era therapeutic approaches Am J Respir Cell Mol Biol 29 2003 S27
29. J.M. Samet Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 161 2000 1
30. J. Hay, and M. Turner-Warwick Interstitial pulmonary fibrosis 1988 Harcourt Brace Jovanovich Philadelphia
31. T.E. King Jr, J.A. Tooze, and M.I. Schwarz Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model Am J Respir Crit Care Med 164 2001 1171
32. J.A. Bjoraker, J.H. Ryu, M.K. Edwin, J.L. Myers, H.D. Tazelaar, and D.R. Schroeder Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 157 1998 199 203
33. Y. Kondoh, H. Taniguchi, and Y. Kawabata Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases Chest 103 1993 1808
34. G. Saydain, A. Islam, and B. Afessa Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit Am J Respir Crit Care Med 166 2002 839
35. G.W. Hunninghake, M.B. Zimmerman, and D.A. Schwartz Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 164 2001 193
36. G. Raghu, Y.N. Mageto, and D. Lockhart The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study Chest 116 1999 1168
37. Flaherty K.R., Mumford J.A., Murray S., Kazerooni E.A., Gross B.H., Colby T.V., et al. Am J Respir Crit Care Med 2003 1;168:543-8
38. Flaherty K., King T., Raghu G., Colby T., Lynch J., Kazerooni E., et al. Idiopathic Interstitial pneumonia: multidisciplinary approach in the diagnosis. Am J Respir Crit Care Med, in press
39. V. Jerek, F. Fucik, and A. Michaljanic The prognostic significance of functional tests in cryptogenic fibrosing alveolitis Bull Europ Physiopath Resp 16 1980 711
40. D.A. Schwartz, R. Helmers, and J. Galvin Determinants of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 149 1994 450
41. H.R. Collard, T.E. King Jr, B.B. Bartelson, J.S. Vourlekis, M.I. Schwarz, and K.K. Brown Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 168 2003 538 542
42. P.I. Latsi, R.M. du Bois, A.G. Nicholson, T.V. Colby, D. Bisirtzoglou, and A. Nikolakopoulou Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends Am J Respir Crit Care Med 168 2003 531 537
43. Lama Am J Resp Crit Care Med 168 2003 1084 1090
44. Hallstrand T.S., Boitano L.J., Johnson W.C., Spada C.A., Hayes J.G., Raghu G. The Timed Walk Test on a measure of severity and survival in idiopathic pulmonary fibrosis. ERJ, in press
45. G.R. Epler, T.C. McLoud, and E.A. Gaensler Normal chest roentgenograms in chronic diffuse infiltrative lung disease N Engl J Med 298 1978 934
46. A.U. Wells, A.D. King, and M.B. Rubens Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography Am J Respir Crit Care Med 155 1997 1367
47. E.A. Gaensler, and C.B. Carrington Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients Ann Thorac Surg 30 1980 411
48. G. Raghu Interstitial lung disease: a diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 151 3 Pt 1 1995 909 914
49. G. Raghu, W.J. Depaso, and K. Cain Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial Am Rev Respir Dis 144 1991 291
50. M.A. Johnson, S. Kwan, and N.J. Snell Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis Thorax 44 1989 280
51. W.W. Douglas, J.H. Ryu, S.J. Swensen Members of the Lung Study Group Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study Am J Respir Crit Care Med 158 1998 220
52. W.W. Douglas, J.H. Ryu, and D.R. Schroeder Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival Am J Respir Crit Care Med 161 4 Pt 1 2000 1172 1178
53. M. Selman, G. Carrillo, J. Salas, R.P. Padilla, R. Perez-Chavira, and R. Sansores Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial Chest 114 1998 507 512
54. R. Ziesche, E. Hofbauer, and K. Wittmann A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis N Engl J Med 341 1999 1264
55. G. Raghu, K.K. Brown, and W.Z. Bradford A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N Engl J Med 350 2004 125
56. J. Behr, K. Maier, B. Degenkolb, F. Krombach, and C. Vogelmeier Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am J Respir Crit Care Med 156 1997 1897 1901
57. G. Raghu, W.C. Johnson, and D. Lockhart Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study Am J Respir Crit Care Med 159 1999 1061